Compare SPRY & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRY | ETW |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.2M | 969.8M |
| IPO Year | 2020 | 2005 |
| Metric | SPRY | ETW |
|---|---|---|
| Price | $7.83 | $9.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 313.2K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $84,278,000.00 | N/A |
| Revenue This Year | $87.40 | N/A |
| Revenue Next Year | $81.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.66 | $8.17 |
| 52 Week High | $18.63 | $9.60 |
| Indicator | SPRY | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 57.96 |
| Support Level | $7.20 | $9.28 |
| Resistance Level | $8.61 | $9.41 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 19.23 | 65.57 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.